A Challenge Trial for COVID-19 Would Not Be the First of Its Kind
A Challenge Trial for COVID-19 Would Not Be the First of Its Kind
Although scientists debate the ethics of deliberately infecting volunteers with SARS-CoV-2, plenty of consenting participants have been exposed to all sorts of pathogens in prior trials.
A Challenge Trial for COVID-19 Would Not Be the First of Its Kind
A Challenge Trial for COVID-19 Would Not Be the First of Its Kind

Although scientists debate the ethics of deliberately infecting volunteers with SARS-CoV-2, plenty of consenting participants have been exposed to all sorts of pathogens in prior trials.

Although scientists debate the ethics of deliberately infecting volunteers with SARS-CoV-2, plenty of consenting participants have been exposed to all sorts of pathogens in prior trials.

food and drug administration
Doctors Forge Ahead with Plasma for COVID-19, Benefits Uncertain
Doctors Forge Ahead with Plasma for COVID-19, Benefits Uncertain
Shawna Williams | Aug 14, 2020
Researchers say the popularity of convalescent plasma makes it more difficult to gather high-quality data on its efficacy.
Activities Discovered for Some Inactive Drug Ingredients
Activities Discovered for Some Inactive Drug Ingredients
Ruth Williams | Jul 23, 2020
Screens of hundreds of drug excipients reveal that some can interact with biological targets, contradicting their FDA categorization as inert.
Former FDA Commissioner Frank Young Dies
Former FDA Commissioner Frank Young Dies
Jef Akst | Dec 2, 2019
The physician-researcher laid the groundwork for genetic cloning and led the US Food and Drug Administration as the country faced the AIDS crisis in the 1980s.
FDA Approves New Cystic Fibrosis Drug
FDA Approves New Cystic Fibrosis Drug
Shawna Williams | Oct 24, 2019
The treatment, Trikafta, increases lung function in most patients with the disease—but comes with a hefty price tag.
Antidepressant Approvals Could Herald New Era in Psychiatric Drugs
Antidepressant Approvals Could Herald New Era in Psychiatric Drugs
Bianca Nogrady | Oct 1, 2019
The FDA has given the green light to the first major new classes of antidepressant therapies in decades, opening up new avenues for therapeutic development.
First New Tuberculosis Drug Approved in 50 Years
First New Tuberculosis Drug Approved in 50 Years
Jef Akst | Aug 15, 2019
The US Food and Drug Administration green lights a therapy for an extreme form of multidrug resistant TB.
Survey of Stem Cell Clinics Reveals Cause for Concern
Survey of Stem Cell Clinics Reveals Cause for Concern
Jef Akst | Aug 1, 2019
Two coauthors of a new study discuss their findings about nearly 170 facilities in the southwestern US selling unproven therapies—and what should be done about them.
Sunscreen Ingredients Absorbed into Blood: Study
Sunscreen Ingredients Absorbed into Blood: Study
Catherine Offord | May 7, 2019
FDA researchers report that multiple active ingredients wind up in users’ bloodstream and recommend toxicology testing to investigate the clinical significance of the findings.
FDA Lifts Import Restrictions on Genetically Engineered Salmon
FDA Lifts Import Restrictions on Genetically Engineered Salmon
Catherine Offord | Mar 11, 2019
The fast-growing fish can now be raised and sold in the US, although it’s likely to be some time before the product hits the market.